To explore the clinical efficacy of Xiaoaiping injection in the chemotherapy of xeloda and oxaliplatin (XELOX) on patients with advanced gastric cancer.

80 cases with advanced gastric cancer treated in our hospital from January 2016 to December 2017 were divided into two groups on the basis of random number table, each with 40 cases. Both groups were treated with XELOX, while the Xiaoaiping group was administrated with Xiaoaiping injection additionally. The clinical efficacy after 2 courses of treatment was assessed. Data were processed in SPSS20.0. The short-term curative effect as well as adverse reactions were expressed in percentages (%) and compared by χ² test. And the inflammatory factors, proportion of peripheral blood immune cells and EORTC QLQ-C30 scores before and after treatment were indicated in mean value±standard deviation and compared by independent t test. A P<0.05 was regarded as significant difference.

The effective rate of the Xiaoaiping group was significantly higher than the control group(80.00% vs. 57.50% P<0.05). After treatment, a remarkable decrease in serum IL-6, TNF-α, CRP concentration, peripheral blood MDSCs and Treg accounted for the proportion of PBMC as compared with those before treatment was found in both groups (P<0.05), and the decrease of the Xiaoaiping group was more significant (P<0.05). After treatment, a great increase in EORTC QLQ-C30 dimensions including physical function, role function, emotional funtion, social function, general health scores was found in both groups, meanwhile a big decrease in symptom dimension score as compared with those before treatment was also found (P<0.05), and the improvement in the aforementioned indicators in the Xiaoaiping group was more significant (P<0.05). No significant difference was found between the two groups in terms of adverse reactions (P>0.05).

In treating patients with advanced gastric cancer, the combination of Xiaoaiping injection with XELOX is effective in improving the clinical efficacy, regulating immune cells, improving inflammatory conditions and life quality of the patients.